![]() ![]() NOTE: DCIS components should not be counted in the determination of HER2 status. Deborah Dillon at Brigham and Women's Hospital,īoston, MA) prior to patient being registered to begin protocol therapy. (HER2/CEP17 ratio ≥2 or an average of ≥6 HER2 gene copies per nucleus) AND confirmedīy Central Pathology Review (Dr. Participants must have histologically or cytologically confirmed HER2-positive diseaseīy local pathology, defined as immunohistochemistry (IHC) 3+ or amplification by FISH This research study is studying an investigational drug as a possible treatment for breastĬancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known Rutter, Morgan, Shellock, Maria, Weitz, MaryAnn, Huff, Kimberly, Jeon, Maryangel, Kasparian, Elizabeth, Lehnus, Jaclyn, Loeser, Wendy, Loeser, Wendy, Lundquist, Debra, Marchetti, Kelly, O'Neil, Kelly, Orechia, Meghan, Padden, Sarah, Pasquale, Kathryn, Mary Roche, Kathleen, A. Spring, Laura, Walsh, Jeanna, Site Research Nurse(s):Abraham, Elizabeth, Aspessi, Michael, William Beeler, Maureen, Bowers, Jordan, Caradonna, Lisa, Caradonna, Lisa, Carrier, Amy, Cronis, Charles, Lewis Freeman, Stefani, Danielle Habin, Karleen, R. 877-DF-TRIAL (87) Trial ID:NCT03587740 View complete trial on Protocol #:18-124 877-DF-TRIAL (87) Condition(s):Breast Cancer Phase: II Principal Investigator:Freedman, Rachel, A Site Investigator(s):Block, Caroline, Briccetti, Frederick, Chi, Dorcas, Faggen, Meredith, G. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |